GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its ...

Hims & Hers (HIMS) defends recovery with personalized healthcare adoption, GLP-1 partnerships, and profit growth. Click here ...

In the battle for weight-loss supremacy, Hims & Hers Health has emerged as a dark horse candidate shaking up the market.